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Patients with the most common and aggressive form of
high-grade glioma, glioblastoma multiforme, have
poor prognosis and fewtreatment options. In 2immuno-
competent mouse brain tumor models (CT26-BALB/c
and Tu-2449-B6C3F1), weshowed thata nonlytic retro-
viral replicating vector (Toca 511) stably delivers an
optimized cytosine deaminase prodrug activating gene
to the tumor lesion and leads to long-term survival
after treatment with 5-ﬂuorocytosine (5-FC). Survival
beneﬁt is dose dependent for both vector and 5-FC,
and as few as 4 cycles of 5-FC dosing after Toca 511
therapy provides signiﬁcant survival advantage. In the
virally permissive CT26-BALB/c model, spread of
Toca 511 to other tissues, particularly lymphoid
tissues, is detectable by polymerase chain reaction
(PCR) over a wide range of levels. In the Tu-2449-
B6C3F1 model, Toca 511 PCR signal in nontumor
tissues is much lower, spread is not always observed,
and when observed, is mainly detected in lymphoid
tissues at low levels. The difference in vector genome
spread correlates with a more effective antiviral restric-
tion element, APOBEC3, present in the B6C3F1 mice.
Despite these differences, neither strain showed signs
of treatment-related toxicity. These data support the
concept that, in immunocompetent animals, a
replicating retroviral vector carrying a prodrug activat-
ing gene (Toca 511) can spread through a tumor mass,
leading to selective elimination of the tumor after
prodrug administration, without local or systemic path-
ology. This concept is under investigation in an ongoing
phase I/II clinical trial of Toca 511 in combination with
5-FC in patients with recurrent high-grade glioma
(www.clinicaltrials.gov NCT01156584).
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S
everal replicating viruses have been evaluated in
preclinical studies of brain cancer, and some are
under clinical investigation.
1–3 Selectivity,
potency, and durability of response are critical attributes
of successful cancer therapy, and we show here that
retroviral replicating vectors (RRVs) based on ampho-
tropic murine leukemia virus (MLV) have properties
that fulﬁll these criteria in animal models.
Toca 511 (vocimagene amiretrorepvec) is a replicat-
ing amphotropic MLV that infects and integrates only
in dividing cells, preferentially in cells with defective im-
munity, such as malignant cells, and, therefore, has
built-in speciﬁcity for replicating malignant cells in
adult animals.
4 The virus stably encodes an optimized
yeast cytosine deaminase (CD) that converts
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ﬂuorocytosine (5-FC), into the potent antineoplastic
drug 5-ﬂuorouracil (5-FU).
5,6 Because the virus is nonly-
tic and 5-FU selectively kills dividing cells, infected cells
may remain and act as a reservoir of virus capable of
infecting new malignant cells during subsequent viral
proliferation.
The 5-FU produced in Toca 511–infected cells is dif-
fusible through cellular membranes
7 and has the poten-
tial to kill neighboring uninfected cancer cells,
enhancing the therapeutic potential via metabolic co-
operation and creating a bystander effect.
8,9 The use of
yeast CD instead of bacterial CD was shown to increase
5-FC to 5-FU conversion by  15 fold.
10 The yeast CD
used here has been optimized for thermostability to
produce an  3-fold increase in activity, compared
with naive yeast CD. These modiﬁcations give Toca
511 an advantage over previously tested strategies
using CD in brain cancer and other cancer models.
A key feature of the retroviral replicating vectors is
reported to be the ability to spread nonlytically and
without signiﬁcant inﬂammatory response.
11 An import-
ant criticism of a number of replicating virus experi-
ments in preclinical models using human xenografts
has been that, although allowing testing against human
tumors, such models do not allow for the role of the
immune system to be evaluated.
1 For example, the con-
tribution of the immune system toward clearance of the
virus or tumor would not be evaluable. Therefore, it is
important to investigate fully the behavior of Toca 511
with 5-FC in one or more immunocompetent models.
Wepresentheretheexperimentalﬁndingsinvestigating
Toca511incombinationwith5-FCtherapyin2immuno-
competent murine orthotopic brain cancer models (CT26
in BALB/c mice and Tu-2449 in B6C3F1 mice). The
objectives of this series of studies were to (1) demonstrate
that Toca 511 can efﬁcientlytransduce and killCT26and
Tu-2449 cells in vitro, (2) determine the optimal intracra-
nial(IC)dosesofToca511incombinationwith5-FCthat
increase survival in orthotopic murine brain cancer
models, (3) demonstrate that Toca 511 antineoplastic
effects are associated with the conversion of 5-FC to
5-FU, (4) determine the biolocalization of Toca 511
after IC administration, and (5) investigate the long-term
survival of brain cancer-implanted mice treated with IC
Toca 511 followed by various 5-FC dose cycles.
We show that transduction with Toca 511, in combin-
ation with 5-FC administration, is effective in treating
implanted IC tumors resulting in tumor eradication and
a signiﬁcant survival advantage. We also show that
Toca 511 is able to convert 5-FC to 5-FU in vivo and
that repeated cycles of 5-FC administration shrink and
prevent further growth of the IC tumor. We have demon-
strated survival beneﬁt without treatment-related toxicity
in mouse strains that are naturally permissive for MLV
replication (BALB/c) and restrictive for MLV infection
(B6C3F1).
12,13 On the basis of previous data from
monkeys with MLV infection,
14 the lack of replication
of amphotropic MLV in human peripheral blood mono-
nuclear cells in vitro,
15 and the presence of effective
anti-MLV APOBEC3 in humans and C57BL/6 but not
BALB/cm i c e ,
16 it is reasonable to expect that humans
will more closely resemble nonpermissive mouse strains
and control Toca 511 spread outside the tumor without
sustained infection of normal tissue. Currently, Toca
511 and 5-FC are being investigated in a phase I/II clin-
ical trial of recurrent high-grade glioma in the United
States (see NCT01156584 at clinicaltrials.gov).
Materials and Methods
Toca 511
A full description of the modiﬁcations and methods used
to generate the Toca 511 vector has been submitted
for publication (O. D. Perez, C. R. Logg, K. Hiraoka, O.
Diago, R. Burnett, A. Inagaki, D. Jolson, K. Amundson,
T. Buckley, D. Lohse, A. Lin, C. Burrascano, C. Ibaþez,
N. Kasahara, H. E. Gruber, D. J. Jolly unpublished
data). In brief, modiﬁcations were made to the plasmid
pACE-GFP
17 to improve stability and increase conveni-
ence of transgene insertion to yield the vector
pAC3-GFP. Genetic enhancements to the wild-type yeast
cytosine deaminase gene were made as follows: (1) the
codon use was optimized for protein synthesis in human
cells, and (2) 3 amino acid changes were introduced
(A23L, I140L and V108I) to increase thermal stability of
the yeast cytosine deaminase protein.
18 The plasmid
pAC3-yCD2 was generated by substituting the modiﬁed
CD gene into pAC3-GFP. Toca 511 is the vector produced
from this plasmid using the production and formulation
methods developed for clinical use.
Mice
Female B6C3F1 mice (age,  8 weeks) were purchased
from Harlan. BALB/c mice (age,  8 weeks) were pur-
chased from The Jackson Laboratory. Mice were
acclimated for 7–14 days after arrival. Mice underwent
surgical placement of an indwelling guide cannula
with a 3.0-mm projection implanted into the right
striatum and ﬁtted with a cap containing a 3.5-mm pro-
jection. The stereotaxic coordinates were AP ¼ 0.5 mm,
ML ¼ 1.8 mm (from bregma).
Cell Culture and Implantation, Delivery, and In-Life
Observations
CT26 colon adenocarcimona cells were chosen over
other possible immunocompetent cancer models,
because these cells were previously used as a brain
cancer model
19 and are well characterized for MLV in-
fection and 5-FC/5-FU sensitivity in a multifocal colo-
rectal cancer metastasis model.
20 CT26 (ATCC#2639)
is a mouse N-nitroso-N-methylurethane–induced
colon adenocarcinoma. The CT26 cell line has also
been used as an immunocompetent model to test viral
therapy in mice.
21 Tu-2449 is awell-established orthoto-
pic glioma model in immunocompetent mice.
22 Tu-2449
cells were derived originally from spontaneously arising
Ostertag et al.: Tumor eradication after delivery of cytosine deaminase and 5-FC
146 NEURO-ONCOLOGY † FEBRUARY 2012tumors in glial ﬁbrillary acidic protein (GFAP)–v-src
transgenic mice.
23 Implanted tumors display an invasive
phenotype and express both the astroglial marker GFAP
and the oncogenic form of signal transducer and activa-
tor of transcription–3 (Stat3) found in many human
gliomas. Both cell lines were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) with 10% fetal
bovine serum, sodium pyruvate, and GlutaMAX
(Hyclone and Invitrogen). Cells were resuspended in
phosphate-buffered saline (PBS; Hyclone) for implant-
ation. CT26 or Tu-2449 cells (1E4 [1 × 10
4]i n1mL)
were infused at 0.2 mL per minute (5 min, followed by
a hold of 5 min) IC through an injection cannula with
a 3.5-mm projection inserted through the guide
cannula. In the experiment shown in Fig. 7, cannulas
were not used. Instead, mice underwent IC inoculation
of Tu-2449 cells and Toca 511 vector into the right
striatum using a Hamilton syringe. The projected stereo-
taxic coordinates were AP ¼ 1.0 mm, ML ¼ 2.0 mm,
DV ¼ 3.5 mm (from midline, bregma, and dura, respect-
ively). For the cell injections in Fig. 7 only, 2 mL of cell
suspension were delivered at a rate of  0.5 mLp e r
minute (4 min total). In all cases, Toca 511 was delivered
in 5 mL over 15 min. Five minutes after completion of in-
fusion of the cells or vector, the infusion assembly was
raised out of the skull and the skin closed. Toca 511
doses are deﬁned as transducing units per gram of brain
(TU/g) with the mean mouse brain deﬁned as 0.5 g.
Virus dosing is described as per gram of brain, because
this has been the convention for viruses that replicate in
brain tissue.
24 It is unclear whether this is the most appro-
priate way to scale for clinical use of Toca 511, but the
obvious alternative, scalingb yb o d yw e i g h t ,g i v e sp r e -
dicted human doses that are almost identical to human
doses scaled by brain weight.
Routine general health, in-life observations, and body
weights were collected throughout the course of the
study. In-life observations were scored on a 0–3 point
systemforseverityofeachsymptom.Micewithacumula-
tive score of 5 were euthanized. Mice with body weight
loss of .20% for .2 days were euthanized. All animal
experiments were approved by either the Institutional
Animal Care and Use Committee (A4487-01) of Explora
(San Diego, California) or the University of Veterinary
Medicine EthicsCommittee andAustriangovernmentau-
thorities (BMBWK-68.205/232-II/10b/2008).
Infectious Vector Production
Infectious RRV was prepared by standard DNA plasmid
transient transfections of 293T cells using the Calcium
PhosphateTransfectionKitfromPromega.Vectorsuper-
natants were transferred onto HT-1080 cells, and the
pooled transductants were used as a vector producer
cell line. The producer cells were expanded and vector
collected and processed using methods analogous to
those used previously for nonreplicative retroviral
vectors
25,26 (US patent 5792643). In brief, cells were
expanded and supernatant harvested over 48 h, clariﬁed,
and treated with benzonase to digest host cellular DNA.
The material was subjected to chromatography through
anion exchange and size exclusion columns. The peak
fractions from the size exclusion column were pooled,
and the vector was formulated in a Tris-sodium chloride
isotonic buffer solution containing 1 mg/mL of human
serum albumin and 10 mg/mL each of sucrose and man-
nitol. Titers of the ﬁnal preparations were determined by
quantitativepolymerasechainreaction(qPCR)expressed
in transducing units (TU)/mL tested on PC-3 cells.
Determination of Titers of Vector Preparations
Titers of vector preparations were determined using
several dilutions of vector preparation on PC-3 cells as
target for infection, adding azidothymidine (AZT) 24 h
after infection to stop vector replication and counting
the number of integrated proviruses in the target cell
population by qPCR. PC-3 cells were seeded on 12-well
plates on day 0 (12–18 h prior to transduction) in 1 mL
complete DMEM at a cell conﬂuence targeting 60% on
the day of transduction. On day 1, the PC-3 cells were
transduced (triplicate transduction for each sample and
dilution) with 20 mL of the diluted vector preparations
(1:20 and 1:200) prepared in complete DMEM in the
presence of 4 mg/mL polybrene. Plates were returned to
the incubator for 24 h and on day 2, AZT was added to
40 mM from a 10 mM stock solution to arrest viral repli-
cation. Cells were harvested on day 3, and the genomic
DNA was prepared from each well of cells using a
Promega Maxwell 16 automated puriﬁcation instrument
with the associated cartridges. The concentration of
DNA was determined using a Nanodrop ND-1000. The
integrity of the DNA was checked by gel electrophoresis
on a 0.8% ethidium bromide agarose gel (Invitrogen
e-gel). qPCR was performed in triplicate with use of
the following primers and probe (Integrated DNA
Technologies): forward primer 5–MLV-U3-B: 5′ AGC
CCACAACCCCTCACTC; reverse primer 3-MLV-PSI:
5′TCTCCCGATCCCGGACGA; and probe FAM-5′C
CCAAATGAAAGACCCCCGCTGACG- BHQ1. qPCR
was performed on a Bio-Rad CFX96 Real Time System.
Theampliconsizeis192 bp.Theseprimersanddetection
probe will only detect the integrated provirus with the
3′UTR transposed to the 5′end of the provirus, and will
not detect any contaminating plasmid DNA used in the
transient transfection step to make the infectious
virus. The proviral copy number was determined using
a 7-log serial dilution standard curve from a proviral-
containing plasmid pAZ3-GFP [21]. DNA from cells
infected with a control vector was included as a positive
control for transfection and qPCR quantitation; controls
without template were run to determine contamination
or background. Titers are typically around E8 (1 × 10
8)
TU/mL.
In Vitro Transduction of Tumor Cells and 5-FC
Sensitivity Calculation
One hundred percent Toca 511–transduced CT26 and
Tu-2449 cells were plated on day 0, and 5-FC
(Nantong Jinghua Pharmaceutical) dissolved in PBS
was added immediately at different concentrations.
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and MTS assay. A 4-parameter curve ﬁt was performed
using the Prism 5 statistical package, and 50% inhibi-
tory concentration (IC50) values were calculated.
Comparison of GFP Expression Level in CT26
and Tu-2449 Cells
The CT26 and Tu-2449 cells were infected with vector
made from pAC3-GFP at a multiplicity of infection
(MOI) of 1.0 or 0.1. After 72 h, cells were resuspended
in PBS and analyzed by ﬂow cytometry for GFP expres-
sion (BD FACS Canto II).
In vivo Survival Studies
On day 0, mice underwent IC implantation of 1E4
Tu-2449 or CT26 cells. On day 4, mice were injected
with Toca 511 or vehicle control (inhibitory concentra-
tion, 5 mL/mouse) by IC infusion at 0.33 mL per minute
(15 min, followed by a hold of 5 min) through an injec-
tion cannula with a 3.5-mm projection inserted through
the guide cannula. For CT26 implants, 9 days were
allowed for vector spread before the ﬁrst intraperitoneal
injection (IP) cycles of 5-FC (500 mg/kg) or PBS twice
per day (BID) dosing were initiated. Each cycle consisted
of 7 days of treatment, followed by 10 days without treat-
ment. Cycles were repeated until termination of the study.
Tissue sample collection was performed at the end of the
survival studies.
For Tu-2449 implants, unless noted otherwise, mice
were treated IP BID for 4 consecutive days with PBS or
5-FC (500 mg/kg/dose) starting on day 10. Cycles of 4
days BID treatment with PBS or 5-FC followed by 10
days of no treatment, to allow viral spread, were
repeated. Tissue sample collection was performed at
the end of the survival studies.
Two different lots of Toca 511 were used for all in
vivo studies. Toca 511 lot T511019-FNL had a starting
titer of 4.7E8 TU/mL, and Toca 511 lot T511015-FNL
had a starting titer of 1.7E8 TU/mL. Figures 2 and 3B
used diluted stock from lot T511019-FNL, as indicated.
Figures 3A, 6, and 7 used diluted stock from lot
T511015-FNL, as indicated. Toca 511 administered
intracranially is expressed as TU per gram of brain as-
suming that the mean mouse brain weighs 0.5 g. As
such, an IC dose that is reported as E6 corresponds to
4.7E6 and 1.7E6 for experiments performed with lots
T511019-FNL and T511015-FNL, respectively, and so
on for doses labeled E3, E4, and E5.
Tumor Processing and HPLC Analysis
Tumors were isolated and portioned if large enough for
multiple analyses (.50 mg). Tumor sections for HPLC
analysis were crushed in a 1.5 mL centrifuge tube using
a plunger from a 1-mL syringe. Crushed samples were
mixed with 150 mL RIPA buffer (Thermo Scientiﬁc
89900) and vortexed vigorously for 10 min. Samples
were spun at 48C at 20000 rcf for 10 min.
Supernatants were removed and mixed thoroughly with
150 mL of 10% trichloroacetic acid and spun as above.
Supernatants were removed for analysis by the Agilent
HPLC unit, with a Hypersil BDS C18 column run isocra-
tically at 1 mL/min with 95% buffer A containing
50 mM ammonium phosphate and 0.1%
tetra-n-butylammonium perchlorate with pH adjustment
of the buffer to 2.1 with phosphoric acid and 5% solvent
B,whichis100%methanol.Theruntimewas5 minwith
each sample run twice. The photodiode detector array
scans 190–350 nm, with chromatograms selected to
display at 285 nm for 5-FC and 264 nm for 5-FU. Data
were expressed in relative milliabsorbance units (mAU)
of peak area from the chromatograms.
Protein Gels, Western Blots, and Tumor PCR
Tumors analyzed by HPLC were also analyzed by
Western blot for CD expression. Tumor fragments were
mixed with a separate aliquot of RIPA lysis buffer, and
20 mg of total protein from each sample was electrophor-
esed on polyacrylamide gels and Western blotted as
described previously (O. D. Perez, C. R. Logg, K.
Hiraoka, O. Diago, R. Burnett, A. Inagaki, D. Jolson,
K. Amundson, T. Buckley, D. Lohse, A. Lin, C.
Burrascano, C. Ibaþez, N. Kasahara, H. E. Gruber, D.
J. Jolly unpublished data). When available, the remaining
pellets were extracted for genomic DNA, and the level of
vector DNA was determined by PCR, as described in the
supplementary materials and methods.
Histological Analysis of Tissues
Individual tissues from nonperfused mice were harvested
at sacriﬁce using disposable instruments to avoid cross
contamination. Tissue samples that were placed in for-
malin were sent for review to a certiﬁed pathologist
(Histo-Scientiﬁc Research Laboratories, Thurmont,
MD). Tissues were processed, embedded in parafﬁn, sec-
tioned, stained with hematoxylin and eosin (H&E) and
were evaluated via light microscopy.
Anti-MLV Enzyme-Linked Immunosorbent Assay
(ELISA)
A capture ELISA was performed on collected serum
samples with MLV capture antigen (viral particle prep-
aration prepared as described in infectious vector pro-
duction, heat-inactivated). In brief, 100 mL/well of
capture antigen (1.56 mg/mL) was incubated overnight
at 2–88C in ELISA 96-well microtiter plates (Corning).
Plates were blocked with blocking buffer for 60–
90 min at 15–308C in constant shaking at 150 RPM
(1× PBS, 1% BSA, 0.05% TW20, 0.05% sodium
azide [PBS; Hyclone], BSA [MP Biomedicals], TMB sub-
strate solution [Southern Biotech], Tween-20 [Sigma],
5% sodium azide solution [VWR]). Serum samples
were added in 2-fold dilutions from 1:50 to 1:1000 in
PBS and incubated for 90 min at 15–308C in constant
shaking at 150 RPM. After washing with PBS, goat
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Biotech, 1:4000 dilution) was added and the plates
were incubated for 70 min at 15–308C in constant
shaking at 150 RPM. After washing for 5 times with
PBS, plates were developed with TMB substrate
(Southern Biotech), and then TMB stop solution was
added after 10 min incubation. Plates were read at
450 nm using an ELISA reader (SpectraMax190;
Beckman Coulter).
Statistical Analyses
Survival data were plotted using the Kaplan-Meier
method and were compared by the log-rank test or
Student’s t-test as noted. P values of ,.05 were consid-
ered to be statistically signiﬁcant in all analyses, which
were done with Prism 5 statistical software (GraphPad
Software).
Results
CT26 and Tu-2449 Cells Respond Similarly to Toca 511
with 5-FC Dose-Dependent Killing and MLV Spread
In Vitro
CT26 and Tu-2449 cells were cultured in vitro as either
nontransduced control or 100% Toca 511 transduced
experimental samples. Sensitivity to 5-FC was deter-
mined by measuring cell viability over time in the
absence or presence of titrating amounts of 5-FC
(Fig. 1A). Both CT26- and Tu-2449–uninfected cells
are highly resistant to 5-FC, whereas those that are
Fig. 1. Comparison of CT26 and Tu-2449 in vitro susceptibility to Toca 511 (511) or MLV expressing GFP (MLV-GFP) vectors. Sensitivity to
5-FC was determined by measuring cell viability (MTS assay) over time in the absence or presence of titrating amounts of 5-FC (A). IC50
values were calculated for CT26 and Tu-2449 cell lines at 4.2 mM (0.5 mg/mL) and 1.5 mM (0.19 mg/mL), respectively. Flow cytometry
analysis was done to measure GFP positive cells transduced by MLV-GFP at an MOI of 1.0 or 0.1 (B).
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manner. A 4-parameter curve ﬁt was performed using
the Prism 5 statistical package and IC50 values calcu-
lated. The dose response curves determined that both
CT26- and Tu-2449–infected cell lines had similar
5-FC IC50 of 4.2 mM and 1.5 mM, respectively.
Analysis of MLV vector spread using a GFP expressing
version of Toca 511 shows that the rate of vector
spread is similar in both CT26 and Tu-2449 cells at
MOI of 0.1 and 1 (Fig. 1B).
Toca 511 in Combination with 5-FC Signiﬁcantly
Improves Survival in the Syngeneic Murine CT26 Tumor
Model
To test the effectiveness of Toca 511 as a therapeutic
agent, cannulated BALB/c mice were implanted with
1E4 (1 × 10
4) CT26 cells intracranially. Various doses
of Toca 511 or vehicle were injected into the tumor
through the same cannula 4 days after cell injection.
After allowing 9 days for vector spread, cycles of 5-FC
(500 mg/kg) or PBS BID dosing were initiated. Each
cycle consisted of 7 days of treatment, followed by 10
days without treatment. Cycles were repeated until ter-
mination of the study.
The lowest Toca 511 dose tested, 1E4 TU/gram of
brain (E4), showed an increase in median survival for
the 5-FC treatment group (40.5 days), compared with
PBS-treated mice (30.5 days) (Fig. 2), that was not stat-
istically signiﬁcant (P ¼ .665). In contrast, Toca 511
treatment at the mid (E5) and high (E6) dose levels in
combination with 5-FC resulted in signiﬁcantly pro-
longed survival, compared with the vector plus PBS
control (P , .0012 and ,.0113, respectively) (Fig. 2).
Quantitative PCR analysis to detect integrated vector
in various tissues was performed on the surviving mice
terminated at approximately day 90 (Supplementary
material, Table S1). The qPCR data show a wide range
of values in the various organs, but the lymphatic/hema-
tological organs consistently had a high mean vector
DNA signal. Because the animals were not exsangui-
nated, much of the signal in other tissues could be attrib-
uted to blood/lymph contamination. A small signal
persisted at the site of injection even after apparent
tumor clearance. Whether this represents residual quies-
cent tumor or other type of signal is not clear. A small
number of mice in the control groups that survived
until the ﬁnal time point did not show visible tumor.
Histological evaluation of the same tissues analyzed for
Toca 511 qPCR was performed. All residual tumors were
conﬁned to the central nervous system (brain) and were
derived from the CT26 implanted cells. All other micro-
scopic ﬁndings were incidental and were not associated
with any toxicity due to Toca 511 (as assessed by a quali-
ﬁed pathologist). Three mice with the highest level of Toca
511 signal in the thymus (777 951, 1 193 632, and
2712 226 copies/mg) (Supplementary material, Table S2)
did not have associated pathology despite the high levels
of integrated retroviral DNA detected in these animals
(as assessed by a qualiﬁed pathologist).
Toca 511 Therapy with 5-FC Signiﬁcantly Improves
Survival in the Syngeneic Tu-2449 Murine Glioma
Model
The Tu-2449 tumor cell line is derived from tumors that
arose spontaneously in GFAP-v-src transgenic mice
23
and has been used as an orthotopic, syngeneic,
Fig. 2. CT26 in BALB/c brain metastasis tumor model survival analysis. Groups of 10 female BALB/c mice (9 weeks of age) were implanted
IC with 1E4 CT26 tumor cells then dosed IC with vehicle (Control) or IC with Toca 511 at 3 dose levels expressed as transducing units per
gram of brain (TU/g) ranging from a dose level of E4 to a dose level of E6 TU/g. Following 9 days, to allow spread of Toca 511, mice were
treated IP BID for 7 consecutive days with either PBS or 5-FC (500 mg/kg) as indicated. The cycle of 7 days on drug followed by 10 days off
drug was repeated until the conclusion of the study. Survival analysis up to day 95 was performed. DNA and RNA PCR analysis to detect
integrated vector in various tissues and viral particles in sera were performed on the mice terminated at day 95.
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mice.
22,27 This model more closely mimics human glio-
blastoma characteristics than some murine models, in
that it forms a diffuse inﬁltrative tumor that quite closely
mimics human glioblastoma multiforme (GBM) behavior
and has been shown to be efﬁciently infected with a repli-
catingMLVexpressingGFPinanorthotopicmodel.
27The
Tu2449 model was therefore used to study Toca 511 plus
5-FC efﬁcacy in an in vivo preclinical setting.
Two separate Tu-2449 glioma model experiments in-
corporating 4 dose levels of Toca 511 were performed.
Toca 511 IC doses ranging from E3 to E6 TU/g were
tested (Fig. 3A and B). After allowing 9 days for vector
spread, cycles of 5-FC (500 mg/kg) or PBS BID dosing
were initiated. Each cycle consisted of 4 days of treat-
ment followed by 10 days without treatment. Cycles
were repeated until termination of the study.
As shown in Fig. 3A, IC Toca 511 dosing at both E6
and E5 dose levels in combination with 5-FC (500 mg/
kg) BID resulted in prolonged survival, compared with
the Toca 511 plus PBS control (median .189 vs. 33
days), and statistically signiﬁcant survival (P , .0036
and ,.0354, respectively). As shown in Fig. 3B, E5
dose and 2 lower Toca 511 dose levels (E4 and E3) in
combination with 5-FC also resulted in prolonged sur-
vival, compared with the Toca 511 plus PBS control
(E5: P , .0005; E4: P , .002; and E3: P , .01).
However, although the E5 vector dose level with the
low 50 mg/kg 5-FC BID dose showed some survival ad-
vantage, compared with control (P , .0198), it was sig-
niﬁcantly less effective than the 500 mg/kg BID dose
(P , .03).
Quantitative PCR analysis of selected tissues for the 2
highest levels of Toca 511 was performed to detect inte-
grated vector in various tissues in the mice terminated at
day 180 (Supplementary material, Table S3). Unlike the
high proviral DNA levels detected in multiple tissues in
some BALB/c mice, surviving B6C3F1 mice did not
Fig. 3. Tu-2449 in B6C3F1 glioma model survival analysis. Groups of 10 female B6C3F1 mice (8 weeks of age) were implanted IC with 1E4
Tu-2449 tumor cells then dosed IC with vehicle (Control) or IC with Toca 511. Two separate experiments were performed with doses ranging
from E3 to a dose level of E6 TU/g (A and B). Following 7 days, to allow spread of Toca 511, mice were treated IP BID for 4 consecutive days
with either PBS or 5-FC 500 mg/kg or 50 mg/kg (low) as indicated. This cycle of 4 days on drug followed by 10 days off drug was repeated
until the conclusion of the study. Survival analysis up to day 180 (A) or day 100 (B) was performed on each group.
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assessed by qPCR. Only low levels of integrated vector
were detected in just a few tissues outside the right side
of the brain where vector was injected. Analysis of
anti-MLV antibody production in Toca 511–treated
BALB/c and B6C3F1 mice over time showed that both
strains of mice produced antibody against Toca 511;
however, antibody production did not correlate directly
to detected vector spread levels in the tissues of the mice
(Table 1).
BALB/c Mice Are More Permissive to Toca 511 than
B6C3F1 Mice after IC Injection of Toca 511
To further characterize the differences seen in the biodis-
tribution of Toca 511 in BALB/c and B6C3F1 mice,
tissue proﬁles of qPCR positivity in tumor-bearing
mice (day 90 and 180, respectively) are shown side by
side (Fig. 4A and B). This demonstrates a strain-speciﬁc
susceptibility in normal tissues to Toca 511.
A contributory phenomenon that could explain the
observed difference in viral distribution between the 2
mouse strains is that BALB/c mice have been shown to
carry an allele of APOBEC3 that does not restrict
MLV, whereas C57BL/6 mice (from which B6C3F1
mice are derived) carry an allele that does.
16 We show
that these previously identiﬁed allelic differences apply
to the mice used in these experiments (Supplementary
material, Fig. S1).
Efﬁcient In Vivo Conversion of 5-FC to 5-FU by Toca
511–Infected Tu-2449 Tumors
Highly efﬁcient intratumoral conversion of the 5-FC
prodrug into the anticancer drug 5-FU was demon-
strated after Toca 511 delivery, followed by intraperito-
neal (IP) or oral gavage (OG) with 5-FC (Fig. 5). Mice
were implanted with Tu-2449 tumors; Toca 511 was
administered at E6 TU/g, and 5-FC dosing was initiated
20 days after Tu-2449 implantation for 2 days BID at
either 500 or 250 mg/kg per day and then again 1 h
before tumor harvesting and processing on the third
day. Brain tumor lysates (2–4/group) as described in
Fig. 5B were analyzed by HPLC. In vivo conversion of
5-FC to 5-FU was detected in all groups given Toca
511 and 5-FC (Fig. 5A and C). The Toca 511 no 5-FC
group had neither 5-FC nor 5-FU detectable signals as
expected (Fig. 5A). The 5-FC only group had detectable
5-FC signals but no signal for 5-FU. Mice given Toca
511 and 5-FC (IP or OG) had comparable levels of
5-FU and very low levels of 5-FC. In all Toca 511 plus
5-FC groups, detection of 5-FC was near background
levels, whereas 5-FU was readily detectable, suggesting
that the optimized CD gene is rapidly converting
almost all of the available 5-FC to 5-FU in the tumor.
Conversion of the signal based on a standard curve
showed that there was 25–125mg 5-FU per gram of
tumor detected at the time of measurement.
Isolated Tu-2449 tumors were also processed for
Western blot analysis of CD expression (Fig. 5B and
C). All groups treated with Toca 511 had readily observ-
able CD expression, whereas mice that were not given
Toca 511 did not have detectable CD protein.
When available, the remaining pellets, after superna-
tants were removed for HPLC analysis, were extracted
for genomic DNA. Extracted samples were analyzed
by qPCR for proviral integration using MLV-LTR
primers and probe. The no vector group DNA was nega-
tive for proviral sequences as expected, and in the other
groups, the copy number/genome ranged from
1.4 copies/genome (208 668 copies/mg) to 15 copies/
genome (2 183 971 copies/mg), with a mean of 2.8
copies/genome and a median of 3.7 copies/genome
(Fig. 5C). Parallel analyses using the envelope (ENV)
and CD gene primers and probes gave similar results.
Toca 511/5-FC Treatment Shrinks IC Tu-2449
Tumors in B6C3F1 Mice
To visualize the in vivo effect of IC Toca 511 treatment
on the Tu-2449 tumors, Toca 511–treated brains from
Tu-2449 glioma model mice were ﬁxed and stained by
H&E for histological analysis at varying times during
5-FC cycles. Mice were sacriﬁced before the ﬁrst 5-FC
dosing cycle, before the second 5-FC dosing cycle, or
before the fourth 5-FC dosing cycle, and brains were
ﬁxed and sectioned (Fig. 6). Four mice were analyzed
at each time. Tumor area or length was measured and
plotted for each group (Fig. 6A). Results show that
between the ﬁrst and second 5-FC dose, the Tu-2449
tumor is still growing (Fig. 6B). However, by the start
of the fourth 5-FC dose, most of the tumor is no
Table 1. Antivector ELISA activity (positive/total) for CT26/in BALB/c and Tu-2449 in B6C3F1 mouse brain tumor models over time
D a y s 1 01 33 03 84 75 26 49 09 81 8 9
Dose BALB/c
E6 nt 1/40 /2n t 1 /3n t 2 /55 /7n t n t
E5 nt nt nt nt nt nt nt 1/8n t n t
E4 nt 0/31 /4n t 0 /3n t 0 /20 /3n t n t
B6C3F1
E6 0/3 n tn t1 /2n t 2 /3 n tn tn t8 /9
E5 0/1 n tn t0 /2n t 0 /2 n tn t5 /84 /7
Abbreviations: nt, not tested.
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ropsies showed that there was no evidence of tumor
spread beyond the immediate vicinity of the skull.
Toca 511–Dependent Signiﬁcant Survival Advantage
Outto 180 Days Requires Only 4Cycles of 5-FC Dosing
Results from the histological analysis in Fig. 6 suggested
that, by the end of the fourth 5-FC dosing cycle, we
could expect that there would no longer be any viable
tumor. To investigate this hypothesis, an additional sur-
vival study was conducted using the Tu-2449 glioma
model. Groups of 10 mice received IC Toca 511 at E3,
E4, or E5 doses and were treated with only 4 cycles of
5-FC (500 mg/kg) once a day (SID). Each cycle con-
sisted of 4 days of treatment (single daily dosing) fol-
lowed by 10 days without treatment. Survival was
assessed until day 180 (Fig. 7). Survival of the mice
during the 5-FC treatments was similar to results seen
in Fig. 3. At day 67, the last dose of 5-FC (cycle 4),
there was no signiﬁcant difference in mean survival of
mice receiving the lowest virus dose (E3) followed by
5-FC or PBS administration (group 1 and 2: 40.4 vs
35.1 days; P ¼ 0.429). However, results from Toca
511 treatment at the E4 and E5 dose levels in combin-
ation with 5-FC resulted in signiﬁcantly prolonged sur-
vival, compared with the Toca 511 plus PBS control
(P ¼ .025 and P , .0009, respectively, Student’s t-test).
At the end of 180 days, 80% of the E5 and 40% of
the E4 dosed mice survived, compared with 100%
death of the control group before the end of 5-FC
dosing. The nonoptimal E3 SID 5-FC dosing did not
show any survival advantage over control. These data
show that treatment with Toca 511 at the mid and
high doses results in the elimination of viable cancer in
most animals after 4 dosing cycles of 5-FC, because
only areas of scarring but no observable tumor were
seen in the animals at the end of study.
Discussion
In these studies in mice with implanted brain tumors, we
have determined (1) that Toca 511 can efﬁciently trans-
duce and, in the presence of 5-FC, kill CT26 and
Tu-2449 cells in vitro and in vivo; (2) that there is a
dose response for Toca 511 in combination with 5-FC;
(3) that Toca 511 antineoplastic effects are attributable
to infection (typically multiple copies/cell) of the
cancer cells, expression of the CD protein, and the
intratumoral conversion of 5-FC to 5-FU; (4) that the
biolocalization of Toca 511 in tissues after IC adminis-
tration depends on the murine host but that, in even
the Tu-2449 model, where signiﬁcant viral spread did
not occur outside the tumor, there is rapid spread
within the tumor; and (5) tumor can be eliminated
from a cancer-implanted mouse treated with Toca 511
after only 4 cycles of 5-FC dosing.
Two different syngeneic murine brain tumor models
were used as models of human brain cancer. The use
of immunocompetent models is critical to the functional
Fig. 4. Tissue proﬁles of qPCR positivity from tumor-bearing murine studies after IC administration of Toca 511. Copies/mg of MLV DNA
detected per tissue (triplicate measures per mouse sample, averaged for cohorts of n ¼ 10) are presented. Breaks in the X-axis represent the
distribution of low (,15 000 copies/mg), medium (15 000–600 000 copies/mg) and high (.600000 copies/mg). (A) Day 90 tissue
positivity proﬁle of tumor bearing BALB/c mice. (B) Day 180 tissue positivity proﬁle of tumor bearing B6C3F1.
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because the immune system may have contrasting inﬂu-
ences on viral spread and therapeutic response.
28
Immunodeﬁcient models using human xenografts may
give a somewhat limited view of the effect of viral
therapies in immunocompetent models or patients.
Both models were successfully treated, and signiﬁcant
survival beneﬁt was achieved at mid (E4) and high (E5
and E6) dose levels of Toca 511. It should be noted
that, in all cases, the survival studies at the mid to high
Fig. 5. 5-FC to 5-FU conversion analysis (A), CD expression (B), and vector copy number (C). Six groups of female B6C3F1 mice (16 mice, 8
weeks of age) were implanted IC with Tu-2449 glioma tumor cells then injected IC with vehicle (Group 2) or IC with Toca 511 (E6 TU,
Groups 1 and 3–6). On day 20, when mice started losing weight, they were treated IP or by oral gavage (OG) BID for 2 consecutive
days with either PBS (Group 1) or 5-FC (500 mg/kg, Groups 3 and 6; or 250 mg/kg, Groups 2, 4, and 5). After 2 days of 5-FC dosing
the mice were given 1 ﬁnal 5-FC dose 1 h before sacriﬁce. Tu-2449 tumors were surgically isolated from the brains for HPLC processing
(A) Select tumors (B) were further trimmed for Western blot analysis (tumors greater than 0.05 g). RIPA lysis supernatants were
processed for HPLC analysis and, when available, RIPA lysis pellets were analyzed by PCR after DNA extraction. (C) Extracted DNA was
obtained from 1, 3, 2, and 2 mice in groups 1, 2, 4, and 5, respectively.
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cially ended early (approximately days 90 and 180) to
conduct analysis of tumor and vector spread. As sup-
ported by Figs 6 and 7, in all likelihood, the mid and
high Toca 511 dose groups no longer had viable
tumors and would have continued to survive with or
without further 5-FC dosing past the 3- and 6-month
cutoff time. Although Toca 511 was injected 4 days
after tumor cell inoculation, this timing did not
prevent tumor engraftment (see Fig. 6) and required
the vector to spread in the tumor. This approach more
closely mimics the clinical procedure of direct, transcra-
nial injection of vector into the tumor, compared with
models in which pretransduced vector-producing
tumor cells and naive tumor cells are mixed before injec-
tion.
29 Injection of vector at 4 days after tumor implant-
ation was necessary to allow time for sufﬁcient vector
spread before 5-FC treatment. Animals died due to
tumor growth as early as 12 days after tumor implant-
ation in both brain cancer models tested. This time
frame is more compressed than in our clinical protocol
but, nonetheless, demonstrates the effectiveness of
Toca 511 against aggressive cancer. 5-FC is converted
to 5-FU at an equal molar ratio.
30 5-FU is likely pro-
duced in excess in the IC Tu-2449 tumor, because the
HPLC analysis showed 5-FU concentrations in the
192–960 mM (25–124 mg/mL) range (based on 1 g of
tumor being approximately equal to 1 mL volume).
This range is 25–620 times greater than the range of
IC50 values for 5-FU for several human glioma cell
lines in vitro (0.2–1 mg/mL).
31
Possible mechanisms that may be acting alone or in
concert to destroy the tumors include direct killing of
the cells by Toca 511–expressed CD-dependent conver-
sion of 5-FC to 5-FU, bystander effect of the excess 5-FU
production killing nontransduced tumor cells,
8,9 and
immune responses to clear the tumor.
32,33 Further
studies remain to be done to determine the contribution
of each of these mechanisms to the cancer clearance
observed in these studies.
Tu-2449tumors isolatedfrommicetreated with Toca
511 and 5-FC showefﬁcient conversion of 5-FC to 5-FU,
and this corresponds with stable transduction of Toca
511 and the CD gene (usually multiple copies) and the
subsequent expression of CD. Efﬁcient and rapid 5-FC
to 5-FU conversion was seen with both IP and OG
delivery of 5-FC, supporting previous reports of efﬁcient
5-FC delivery across the blood-brain barrier.
34 Hlavaty
et al. screened 9 human glioma cell lines for RRV
spread, CD delivery, and conversion of 5-FC to 5-FU
and found that all 9 lines supported RRV spread and
showed sensitivity toward 5-FC at concentrations
observed in human blood after conventional antifungal
5-FC administration.
27 Tai et al. demonstrated that a
prototype of Toca 511 had therapeutic effect in combin-
ation with 5-FC in human glioma U87 orthotopic xeno-
grafts, further supporting the potential of Toca 511 and
5-FC in treating GBM.
11 Other studies of human glioma
xenografts have shown therapeutic response to 5-FU and
to 5-FC after CD gene delivery.
31,35 At least 1 group has
tried treating gliomas with encapsulated 5-FU delivered
intracranially. A phase II trial testing 5-FU encapsulated
inpoly (L-D) lactide-co-glycolide inconjunction with ra-
diation against radiation alone in recurrent malignant
glioma showed a trend in favor of the encapsulated
5-FU arm, compared with the radiation alone arm, in
median survival (15.2 vs 13.5 months).
36 Clear evidence
of tumor necrosis was visible where the encapsulated
5-FU was deposited in the tumor. This supports the
concept that 5-FU can have an effect against brain
tumors in humans if it can be efﬁciently delivered to
the tumor.
Toca 511 spread extensively to lymphoid and other
tissues in permissive BALB/c mouse models, whereas
the nonpermissive B6C3F1 mouse model largely con-
trolled spread beyond the tumor. This observation is
compatible with biolocalization data from non-tumor
bearing mice of both strains up to 180 days after IC
delivery of Toca 511 (O. D. Perez, D. Valenta, O.
Diago, D. M. Jolson, K. Wong, A. P. GalvÐo da Silva,
C. Anderson, D. Gammon, A. Lin, K. Amundson, T.
Buckley, D. Ostertag, F. Lopez Espinoza, B. Martin, R.
Burnett, P. L. Pettersson, C. Burrascano, C. Chen, C.
E. Ibanez, J. M. Robbins, H. E. Gruber, D. J. Jolly un-
published data); BALB/c mice exhibited a higher magni-
tude of qPCR positivity across all tissues than did
B6C3F1 mice. In a previous publication, Tai et al.
11
Fig. 6. Volume and histological analysis of Tu-2449 tumors before
5-FC cycles. (A) Average tumor size (+/2 sem, Dorsal-Ventral
(DV) or Lateral (L) in mM) from before 1st 5-FC dose, before 2nd
5-FC dose, and before 4th 5-FC dose, N ≥ 4. (B) H&E stains of
tumor sections from brains of mice from the three groups analyzed.
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cranially infected human U87 IC xenografts in nude
mouse models using the previous generation
CD-expressing MLV. Difference in mouse strains,
because nude mice do not possess many T cells, and
the differences in the PCR assays mayaccount for the ap-
parent disparity. The current quantitative qPCR assay is
a more sensitive detection method than that used by Tai
et al., who used different primers and gel band detection.
However, Tai et al. detected a robust signal in the tumor,
and as we have shown this is the site of rapid viral DNA
sequence accumulation, we believe that the data are
qualitatively compatible. Duerner et al.
37 used a SCID
mouse (CB-17, Charles River) subcutaneous xenograft
model either pre-infected with amphotropic MLV or
infused afterward. They looked for virus in brain,
spleen, bone marrow, liver, lung, kidney, heart, and
target tumor and saw results that appear to resemble
ours in that there is mostly vector in the lymphocytic
compartments in these mice. However, it is not unex-
pected to see such variation between the different
studies when using different mouse strains and different
PCR technologies.
Typically, high retroviral copy number has been asso-
ciated with pathogenicity,
38 but we have observed some
individual BALB/c mice that have very high vector copy
numbers (e.g., up to 2.7 million copies/mg equivalent to
18 copies/diploid genome in 1 thymus; see
Supplementary material, Table S2) but that display no
visible or histological abnormalities. It has long been
known that the capacity for MLV to induce tumorigen-
esis in mice is dependent on several factors, including the
mouse strain and timing of infection, and it is also pos-
sible that the 5-FC administration eliminates infected
rapidly dividing cells that correspond to an induced
tumor, but the high vector copy number is surprising.
Mice were not perfused in these experiments, because
we judged that perfusion would not have deﬁnitively
removed all of the blood contamination for assessment
of signal in other tissues and that there was a high prob-
ability that perfusion could have contaminated other
organs during the process. Therefore, the presence of
blood could have contributed to positive signals
observed in the nonlymphoid tissue, and we believe
that much of the broad biodistribution of Toca 511
seen in nonlymphoid tissue was likely the result of
blood retained in the tissue. Nevertheless, those tissues
with higher Toca 511 signal than that detected in the
blood can be considered to be genuinely positive.
The normal route of MLV transmission in mice is ver-
tically from mother to offspring.
12 Both BALB/c mice
and B6C3F1 mice are considered to have functioning
immune systems. However, BALB/c mice express en-
dogenous MLV in young mice, and this at least partially
tolerizes the BALB/c mice to MLV.
13 This is not the case
in C57BL/6 mice,
12 which areone of the parental strains
Fig. 7. Tu-2449 in B6C3F1 glioma model survival analysis after only 4 cycles of 5-FC. Groups of 10 female B6C3F1 mice (8 weeks of age)
were implanted IC with 1E4 Tu-2449 tumor cells then dosed IC with vehicle (Control) or IC with Toca 511. Doses of E3, E4, or E5 TU/go f
Toca 511 were given as indicated. Following 7 days, to allow spread of Toca 511, mice were treated IP once a day (SID) for 4 consecutive
days with either PBS or 5-FC (500 mg/kg) as indicated. This cycle of 4 days on drug followed by 10 days off drug was repeated for only 4
cycles with treatment stopping at day 57. After the last 5-FC dosing regimen, survival analysis was carried out further to day 180.
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allow for a more robust antiviral cellular immune re-
sponse in the B6C3F1 mice, compared with the BALB/
c mice. Finally, it is known that BALB/c mice carry a
splice variant of the APOBEC3 gene that is ineffective
against MLV infection, whereas an allele effective
against MLV infection is expressed in C57BL/6
16 and,
as we show, in B6C3F1 mice. The emerging consensus
is that mouse APOBEC3 (mA3) is a major determinant
of restriction of MLV infection. The notion that mA3 re-
striction plays an important but not absolute role in
MLV infection is further supported by recent reports
comparing the progression of pathogenicity and neutral-
izing antibody production in mA3+/+ and mA32/2
mice of mA32/2.
16,38,39 Although other factors may
contribute to the observed difference in Toca 511 biodis-
tribution, the differences in tolerance and APOBEC3
allelic expression likely account for the observed differ-
ences in viral spread outside of tumors. The data from
the B6C3F1 mouse model support the original
concept
11 that retroviral replication is suppressed in
normal tissues in immunocompetent adult animals but
is not restricted in tumors. We note here that human
APOBEC3G (hA3G) has been shown to be somewhat
more active against MLV than the active form of
mA3.
40 Spread of Toca 511 is likely determined by a
combination of factors, including inherited viral restric-
tion components, prior MLV exposures, and innate and
adaptive immune system defects from mutations
acquired during oncogenesis.
4
The tumor selectivity of amphotropic MLV is attrib-
utable to 2 major factors. First, cancers are hyperproli-
ferative disorders and have a higher mitotic index than
most normal tissues where proliferation, if it occurs, is
carefully regulated. The mitotic index of rodent tumor
models is 10%–77%,
41–43 which has been shown to
be sufﬁcient for therapeutic spread through the tumor
in the studies presented here. Human glioblastomas
have mitotic indices that are usually in this range
(10%–30%
44) that therefore seems sufﬁcient for Toca
511 spread in clinical subjects, with the potential for
therapeutic beneﬁt. Second, cancer progression typically
creates an internally immune privileged environment
within tumors, including GBM tumors, and further pre-
vents the proper signaling of white blood cells to recog-
nize and attack the cancer.
6,45 The same mutations in
malignant cells that create an immune suppressive
microenvironment likely allow increased viral replica-
tion within the cancer.
6,45,46 Furthermore, in the case
of brain cancers, vector spread is likely enhanced by
the immune privileged nature of the brain environment.
However, although considered to be an immune privi-
leged site, the brain is still capable of mounting an anti-
viral response against viral infection.
47,48 The potential
of this response to limit Toca 511 spread is unclear.
Our results suggest that whatever antiviral response
may be occurring, Toca 511 still spreads sufﬁciently
for therapeutic response in the mouse models reported
here. These results in preclinical animal studies suggest
that, in humans, the immune system will exert control
over the virus in healthy cells and tissues and allow
spread in GBM tumors.
To conclude, we report that Toca 511, a replicating
MLV-based vector expressing the yeast CD gene, can
successfully act as a cancer therapeutic in conjunction
with 5-FC to treat both CT26 and Tu-2449 tumors in
an orthotopic brain cancer setting in immunocompetent
animals. In a formal toxicology study, the combination
of Toca 511 and 5-FC was well tolerated and did not
cause any apparent excess toxicity over the course of 6
months. These results form part of the preclinical
support for the human clinical investigation of Toca
511 plus 5-FC as a treatment for GBM and other
cancers. Recently, a ﬁrst in human phase I/II clinical
trials was initiated in patients with recurrent high-grade
glioma, such as GBM (NCT01156584, www.
clinicaltrials.gov).
Supplementary Material
Supplementary material is available at Neuro-Oncology
Journal online (http://neuro-oncology.oxfordjournals.
org/).
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